4564.T OncoTherapy Science (JPX) falls to JPY 22.00 Jan 14, 2026: Earnings ahead
4564.T stock fell -8.33% to JPY 22.00 on 14 Jan 2026, making it one of the JPX’s most active names by volume today. Trading volume hit 35,304,800.00 shares against an average of 58,329,469.00, reflecting heavy intraday flows as traders reposition ahead of a scheduled earnings announcement on 2026-01-30. The move ties directly to clinical development headlines and valuation re-rating in the Healthcare sector in Japan.
Price action for 4564.T stock and liquidity
The main fact today is the intraday drop to JPY 22.00, from a previous close of JPY 24.00, a -8.33% change. Volume reached 35,304,800.00 versus an average of 58,329,469.00, giving a relative volume of 0.64 and confirming the ‘most active’ session status on the JPX.
Fundamentals and valuation of OncoTherapy Science, Inc. (4564.T)
OncoTherapy Science (4564.T) reports trailing EPS of -2.83 and a negative PE of -8.13, with market cap around 7,789,122,799.00 JPY. Key balance-sheet strengths include cash per share JPY 5.26 and a current ratio of 8.63, but price-to-sales sits at 8.14, flagging a premium to revenue given ongoing losses.
Clinical pipeline, catalysts and upcoming events
Clinical progress and licensing news drive investor sentiment: Phase III data on the S-588410 vaccine and other program updates are near-term catalysts. The company lists an earnings announcement on 2026-01-30, which market participants view as the primary event that could reverse or accelerate current price action.
Technical setup and trading signals for 4564.T stock
Momentum indicators show short-term strength mixed with overbought signals: RSI at 68.81 and MACD histogram at 0.40. Bollinger upper band sits at 23.10 and ATR is 1.54, indicating elevated volatility with a tight band around the current price and potential for rapid moves as news arrives.
Meyka AI rates 4564.T with a score out of 100
Meyka AI rates 4564.T with a score of 65.48 out of 100 — Grade B, suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecast signals. These grades are informational only and not financial advice.
Risks and opportunities for investors
Upside depends on positive clinical or licensing news and clearer commercial paths for peptide vaccines and small molecules; downside centers on continued operating losses and trial setbacks. With high cash buffers but negative margins, common risks include binary trial outcomes and dilution if capital raises are required.
Final Thoughts
Key takeaways: 4564.T stock closed at JPY 22.00 on 14 Jan 2026, down -8.33%, and recorded 35,304,800.00 shares traded. OncoTherapy’s fundamentals show significant cash per share (JPY 5.26) and heavy R&D intensity (R&D/revenue ~53.91%), but negative EPS (-2.83) and a negative PE point to ongoing losses. Meyka AI’s forecast model projects a yearly target of JPY 16.73, implying an implied downside of -23.96% versus today’s price; the model also gives a monthly level near JPY 21.15. For traders, the upcoming 2026-01-30 earnings and clinical readouts are immediate catalysts. Our practical price targets for scenario planning are a conservative upside target of JPY 27.00 (implied +22.73%) and a downside stress level of JPY 15.00 (implied -31.82%). Forecasts are model-based projections and not guarantees. Use position sizing and watch JPX order flow and clinical PRs closely; Meyka AI provides this AI-powered market analysis platform data to help frame trading decisions.
FAQs
What drove today’s move in 4564.T stock
Today’s fall in 4564.T stock to JPY 22.00 was driven by heavy trading ahead of the company earnings on 2026-01-30 and ongoing clinical-program news. Volume spiked to 35,304,800.00, indicating short-term repositioning by institutional and retail traders.
Is 4564.T stock a buy after the drop
Given current fundamentals, Meyka AI assigns 4564.T stock a Grade B and a HOLD suggestion; cash per share is JPY 5.26 but EPS is negative (-2.83). Buying depends on risk tolerance, clinical outlook, and willingness to accept trial binary risk.
What are the main catalysts for 4564.T stock soon
Primary catalysts for 4564.T stock are the upcoming earnings on 2026-01-30 and any Phase III or licensing updates for S-588410 and other programs. Positive trial or deal news would likely drive meaningful upside on the JPX.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
